Braverman Award Lecture
Posted By Braverman IVF & Reproductive Immunology || 24-July-2018
Dr Caterina Tiozzo, 2017 recipient of the Braverman Reproductive Immunology Research Grant, presented her work at the 38th ASRI meeting, held in Shanghai, China
At Braverman Reproductive Immunology, we are constantly studying the latest discoveries in the field of reproductive immunology, assessing their efficiency and safety, promoting their use to offer you better diagnostic, monitoring and treatments and help you achieve a healthy pregnancy.
To support emerging breakthrough studies, Dr Braverman created jointly with the American Society of Reproductive Immunology, the Braverman Reproductive Immunology Research Grant.
This competition is designed to recognize emerging research in the field of Reproductive Immunology that leads to clinical application
Dr Mansouri-Attia (Research Associate at Braverman Reproductive Immunology) introducing the Braverman Reproductive Immunology Research Grant at the 38th ASRI meeting, Shanghai, China
Dr Caterina Tiozzo, last year recipient of the Braverman grant award presented her work during the ASRI lecture award session. Dr Tiozzo, MD, PhD, neonatal medicine specialist at NYU-Winthrop, discussed how extracellular vesicles (containing micro RNA) mediate the crosstalk between the mother and fetus thus influencing each other health.
Dr Tiozzo presenting her research work at the 38th ASRI meeting, Shanghai, China
Her project aimed to determine the role of miR-519c (micro RNA) during pregnancy whose dysregulation could lead to major pregnancy complication including pre-eclampsia and preterm labor by inducing excessive placental inflammatory response.
Dr Tiozzo presented how in pre-eclampsia (PE), this placental specific micro RNA (miR519c), detectable in the maternal blood, is reduced and leads to an increase in TNF alpha levels (pro-inflammatory cytokine) and inflammation. miR-519c is found in the serum of normal pregnancy and is highly reduced in the serum of PE patients. Can miR-519c be used as a predictive biomarker for PE or other pregnancy complications?
Although these results are preliminary and require further investigations on a larger sample size, this work may be used to detect early on the women at risk for PE or any pregnancy complications linked to placenta inflammation.
Dr Tiozzo is grateful for receiving the Braverman Reproductive Immunology Research Grant, allowing her to run her project and generate very promising data.